Cyclophosphamide as a first-line therapy in LGL leukemia

Leukemia

Volumn 28, Issue 5, 2014, Pages 1134-1136

  Moignet, A ^a   Hasanali, Z ^b   Zambello, R ^c   Pavan, L ^c   Bareau, B ^d   Tournilhac, O ^e   Roussel, M ^a   Fest, T ^a,g   Awwad, A ^b   Baab, K ^b   Semenzato, G ^c   Houot, R ^a,f,g   Loughran, T P ^b   Lamy, T ^a,f,g  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b PENN STATE CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^d Technicolor Rennes Research and Innovation Cesson Sévigné   (France)

^e Hôpital Estaing   (France)

^f INSERM   (France)

^g UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISONE;

ANEMIA; AUTOIMMUNE DISEASE; BLOOD CELL COUNT; FEBRILE NEUTROPENIA; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LETTER; LYMPHOCYTOSIS; NEUROPATHY; NEUTROPHIL COUNT; PHENOTYPE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RETROSPECTIVE STUDY; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VASCULITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; MALE; MIDDLE AGED;

EID: 84899968261     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.359     Document Type: Letter

References (19)

1. Loughran Jr. TP. Clonal diseases of large granular lymphocytes. Blood 1993; 82: 1-14.
2. Loughran Jr. TP, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C. et al. Leukemia of large granular lymphocytes: Association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med 1985; 102: 169-175.
3. Sokol L, Loughran Jr. TP. Large granular lymphocyte leukemia. Oncologist 2006; 11: 263-273.
4. Lamy T, Loughran Jr. TP. Clinical features of large granular lymphocyte leukemia. Semin Hematol 2003; 40: 185-195.
5. Jerez A, Clemente MJ, Makishima H, van Adrichem AJ, Kuusanmäki H, Andersson EI. et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012; 120: 3048-3057.
6. Koskela HL, Eldfors S, Ellonen P, Koskela H, LeBlanc F, Peng NgK. et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl JMed 2012; 366: 1905-1913.
7. Fasan A, Kern W, Grossmann V, Haferlach C, Haferlach T, Schnittger S. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia 2012; 27: 1598-1600.
8. Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagström S. et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013; 121: 4541-4550.
9. Teramo A, Gattazzo C, Passeri F, Lico A, Tasca G, Cabrelle A. et al. Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-Type large granular lymphocyte leukemia. Blood 2013; 121: 3843-3854.
10. Loughran Jr. TP, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 1994; 84: 2164-2170.
11. Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood 2001; 98: 483-485.
12. Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A. et al. Long-Term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-Associated pure red cell aplasia: A Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 2008; 93: 1555-1559.
13. Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O. et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: A report on 229 cases. Haematologica 2010; 95: 1534-1541.
14. Lamy T, Loughran Jr. TP. How I treat LGL leukemia. Blood 2011; 117: 2764-2774.
15. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran Jr. TP. The lymphoproliferative disease of granular lymphocytes: Updated criteria for diagnosis. Blood 1997; 89: 256-260.
16. Morice WG, Kurtin PJ, Tefferi A, Hanson CA. Distinct bone marrow findings in Tcell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood 2002; 99: 268-274.
17. Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: A T-cell clonopathy of undetermined significance? Blood 1994; 84: 1620-1627.
18. Mohan SR, Clemente MJ, Afable M, Cazzolli HN, Bejanyan N, Wlodarski NW. et al. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica 2009; 94: 1407-1414.
19. Loughran Jr. TP, Yao X, Bennett JM, Litzow MR, Evens AM, Tallman MS. Results of a prospective multicenter phase ii study of initial treatment with methotrexate in LGL leukemia (ECOG Protocol E5998). ASH Annual Meeting Abstracts 2010; 116: 702.